AstraZeneca`s Biologic Imjudo (tremelimumab) Receives Approval in the U.S.
WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.
AstraZeneca's Biologic Imjudo (Tremelimumab) Receives Approval in the U.S.
British-Swedish drugmaker AstraZeneca on Thursday said it has received approval from the Indian drug regulator for its anti-liver cancer drug tremelimumab combination in India.nnnRead more at:nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cdsco-approves-astrazenecas-anti-liver-cancer-drug-combination/articleshow/100683439.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
AstraZeneca`s Tremelimumab Receives Approval in Europe
AstraZeneca`s Imjudo (Tremelimumab) Receives Approval in Europe
AstraZeneca`s Imjudo (Tremelimumab) Approved In Europe
AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations have been approved in the European Union (EU) for the treatment of advanced liver and lung cancers.
In a lawsuit filed Monday in Delaware federal court, BMS alleged AstraZeneca’s new CTLA-4 inhibitor Imjudo—approved last year alongside AZ’s Imfinzi in liver and lung cancer—treads on a pair of patents linked to BMS' cancer blockbuster Yervoy.
he Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) to treat advanced liver, biliary tract, and lung cancers.